343 related articles for article (PubMed ID: 21554565)
21. Efficacy and tolerability of naltrexone in the treatment of alcohol dependence: oral versus injectable delivery.
Roozen HG; de Waart R; van den Brink W
Eur Addict Res; 2007; 13(4):201-6. PubMed ID: 17851241
[TBL] [Abstract][Full Text] [Related]
22. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse.
Chick J; Anton R; Checinski K; Croop R; Drummond DC; Farmer R; Labriola D; Marshall J; Moncrieff J; Morgan MY; Peters T; Ritson B
Alcohol Alcohol; 2000; 35(6):587-93. PubMed ID: 11093966
[TBL] [Abstract][Full Text] [Related]
23. A risk-benefit assessment of naltrexone in the treatment of alcohol dependence.
Berg BJ; Pettinati HM; Volpicelli JR
Drug Saf; 1996 Oct; 15(4):274-82. PubMed ID: 8905252
[TBL] [Abstract][Full Text] [Related]
24. Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial.
Korthuis PT; Lum PJ; Vergara-Rodriguez P; Ahamad K; Wood E; Kunkel LE; Oden NL; Lindblad R; Sorensen JL; Arenas V; Ha D; Mandler RN; McCarty D;
Addiction; 2017 Jun; 112(6):1036-1044. PubMed ID: 28061017
[TBL] [Abstract][Full Text] [Related]
25. Response to Degenhardt et al.: 'depot naltrexone use for opioid dependence in Australia: large-scale use of an unregistered medication in the absence of data on safety and efficacy'.
Brewer C
Drug Alcohol Rev; 2008 Jul; 27(4):447-8; author reply 448-9. PubMed ID: 18584398
[No Abstract] [Full Text] [Related]
26. Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial.
Solli KK; Latif ZE; Opheim A; Krajci P; Sharma-Haase K; Benth JŠ; Tanum L; Kunoe N
Addiction; 2018 Oct; 113(10):1840-1849. PubMed ID: 29806872
[TBL] [Abstract][Full Text] [Related]
27. Intramuscular extended-release naltrexone: current evidence.
Gastfriend DR
Ann N Y Acad Sci; 2011 Jan; 1216():144-66. PubMed ID: 21272018
[TBL] [Abstract][Full Text] [Related]
28. Improving clinical outcomes for naltrexone as a management of problem alcohol use.
Hulse GK
Br J Clin Pharmacol; 2013 Nov; 76(5):632-41. PubMed ID: 22946873
[TBL] [Abstract][Full Text] [Related]
29. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.
Hulse GK; Morris N; Arnold-Reed D; Tait RJ
Arch Gen Psychiatry; 2009 Oct; 66(10):1108-15. PubMed ID: 19805701
[TBL] [Abstract][Full Text] [Related]
30. Retention in naltrexone implant treatment for opioid dependence.
Kunøe N; Lobmaier P; Vederhus JK; Hjerkinn B; Hegstad S; Gossop M; Kristensen O; Waal H
Drug Alcohol Depend; 2010 Sep; 111(1-2):166-9. PubMed ID: 20570059
[TBL] [Abstract][Full Text] [Related]
31. Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients.
Pettinati HM; Gastfriend DR; Dong Q; Kranzler HR; O'Malley SS
Alcohol Clin Exp Res; 2009 Feb; 33(2):350-6. PubMed ID: 19053979
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and tolerability of naltrexone in the management of alcohol dependence.
Garbutt JC
Curr Pharm Des; 2010; 16(19):2091-7. PubMed ID: 20482515
[TBL] [Abstract][Full Text] [Related]
33. A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence.
Larney S; Gowing L; Mattick RP; Farrell M; Hall W; Degenhardt L
Drug Alcohol Rev; 2014 Mar; 33(2):115-28. PubMed ID: 24299657
[TBL] [Abstract][Full Text] [Related]
34. Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trial.
Everly JJ; DeFulio A; Koffarnus MN; Leoutsakos JM; Donlin WD; Aklin WM; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
Addiction; 2011 Jul; 106(7):1309-18. PubMed ID: 21320227
[TBL] [Abstract][Full Text] [Related]
35. Extended-release naltrexone and harm reduction counseling for chronically homeless people with alcohol dependence.
Collins SE; Duncan MH; Smart BF; Saxon AJ; Malone DK; Jackson TR; Ries RK
Subst Abus; 2015; 36(1):21-33. PubMed ID: 24779575
[TBL] [Abstract][Full Text] [Related]
36. Long-acting injectable naltrexone for the treatment of alcohol dependence.
Mannelli P; Peindl K; Masand PS; Patkar AA
Expert Rev Neurother; 2007 Oct; 7(10):1265-77. PubMed ID: 17939765
[TBL] [Abstract][Full Text] [Related]
37. Medical management of alcohol dependence: clinical use and limitations of naltrexone treatment.
Volpicelli JR; Volpicelli LA; O'Brien CP
Alcohol Alcohol; 1995 Nov; 30(6):789-98. PubMed ID: 8679021
[TBL] [Abstract][Full Text] [Related]
38. Phase I study of injectable, depot naltrexone for the relapse prevention treatment of opioid dependence.
Xuyi W; Juelu W; Xiaojun X; Haiyan L; Zheyuan L; Zhehui G; Guoming D; Gang L; Jin L; Wei H
Am J Addict; 2014; 23(2):162-9. PubMed ID: 24107112
[TBL] [Abstract][Full Text] [Related]
39. Advances in opioid antagonist treatment for opioid addiction.
Ling W; Mooney L; Wu LT
Psychiatr Clin North Am; 2012 Jun; 35(2):297-308. PubMed ID: 22640757
[No Abstract] [Full Text] [Related]
40. Harm reduction with pharmacotherapy for homeless people with alcohol dependence: protocol for a randomized controlled trial.
Collins SE; Saxon AJ; Duncan MH; Smart BF; Merrill JO; Malone DK; Jackson TR; Clifasefi SL; Joesch J; Ries RK
Contemp Clin Trials; 2014 Jul; 38(2):221-34. PubMed ID: 24846619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
